目的 探討珍龍醒腦膠囊聯(lián)合丁苯酞治療急性腦梗死的臨床療效。方法 選取2018年10月—2020年12月河南科技大學(xué)第二附屬醫(yī)院治療的86例急性腦梗死患者，根據(jù)隨機(jī)數(shù)字法將所有患者分為對(duì)照組和治療組，每組各43例。對(duì)照組靜脈滴注丁苯酞氯化鈉注射液，100 mL/次，2次/d。治療組在對(duì)照組治療基礎(chǔ)上口服珍龍醒腦膠囊，2粒/次，2次/d。兩組用藥治療14 d。觀察兩組的臨床療效和癥狀緩解時(shí)間，比較兩組神經(jīng)功能缺損程度（NIHSS）評(píng)分、同型半胱氨酸（Hcy）、N末端前腦鈉肽（NT-proBNP）、D-二聚體（D-D）、超敏C反應(yīng)蛋白（hs-CRP）的變化情況。結(jié)果 治療后，治療組總有效率是97.67%，顯著高于對(duì)照組的79.07%（P＜0.05）。治療后，治療組出現(xiàn)眩暈、頭痛、中樞性面癱、肢體無(wú)力緩解時(shí)間均短于對(duì)照組（P＜0.05）。治療后，兩組NIHSS評(píng)分均較治療前顯著降低（P＜0.05）；治療后，治療組患者NIHSS評(píng)分低于對(duì)照組（P＜0.05）。治療后，兩組血清因子Hcy、NT-proBNP、D-D、hs-CRP水平均顯著降低（P＜0.05）；治療后，治療組血清因子水平低于對(duì)照組（P＜0.05）。治療組不良反應(yīng)發(fā)生率是6.98%，顯著低于對(duì)照組的16.28%（P＜0.05）。結(jié)論 珍龍醒腦膠囊聯(lián)合丁苯酞治療急性腦梗死具有較好的臨床療效，可明顯改善患者癥狀，有效改善患者神經(jīng)功能缺損程度，并能降低機(jī)體炎性反應(yīng)，且安全有效。

Objective To explore the clinical study of Zhenlong Xingnao Capsules combined with butylphthalide in treatment of acute cerebral infarction. Methods A total of 86 patients with acute cerebral infarction treated in the Second Affiliated Hospital of Henan University of Science and Technology from October 2018 to December 2020 were selected, and all patients were divided into control group and treatment group according to random number method, with 43 cases in each group. Patients in the control group were iv administered with Butylphthalide and Sodium Chloride Injection, 100 mL/time, twice daily. Patients in the treatment group were po administered with Zhenlong Xingnao Capsules on the basis of the control group, 2 grains/time, twice dialy. Both groups were treated for 14 d. The clinical efficacy and symptom relief time of the two groups were observed, and the changes of neurological impairment score (NIHSS), homocysteine (Hcy), N-terminal forebrain natriuretic peptide (NT-probNP), D-dimer (D-D) and hypersensitive C-reactive protein (hs-CRP) in the two groups were compared. Results After treatment, the total effective rate of treatment group was 97.67%, significantly higher than 79.07% of control group (P < 0.05). After treatment, the relief time of vertigo, headache, central facial paralysis, and limb weakness in the treatment group was shorter than that in the control group (P < 0.05). After treatment, NIHSS scores in both groups were significantly lower than those before treatment (P < 0.05). After treatment, NIHSS score in treatment group was lower than that in control group (P < 0.05). After treatment, the levels of serum factors Hcy, NT-probNP, D-D, and hs-CRP in two groups were significantly decreased (P < 0.05). After treatment, the level of serum factor in treatment group was lower than that in control group (P < 0.05). The incidence of ADR in treatment group was 6.98%, significantly lower than that in control group (16.28%) (P < 0.05). Conclusion Zhenlong Xingnao Capsules combined with butylphthalide has good clinical effect in treatment of acute cerebral infarction, and can obviously improve the symptoms of patients, effectively improve the degree of neurological impairment of patients, and can reduce the body inflammatory reaction, which is safe and effective.

R971

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目(LHGJ20200598)